US approves first drug that slows type 1 diabetes progression
The U.S. The FDA has expanded approval of Tzield (teplizumab), making it the first disease-modifying therapy for children and adolescents newly diagnosed with stage 3 type 1 diabetes. They made the announcement on Monday, June 15. The updated authorization covers patients aged 8 to 17 who have recently received a diagnosis. Rather than replacing insulin […]
US approves first drug that slows type 1 diabetes progression Read More »









